← Back to Search

Local Anesthetic

Liposomal Bupivacaine for Postoperative Pain

Phase 4
Waitlist Available
Led By Brian McAllister, MD
Research Sponsored by Northern Light Mercy Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured intraoperatively, in pacu at 4 hours post-op, and at 24,48, and 72 hours post-op.
Awards & highlights

Study Summary

This trial is studying if a new anesthetic drug can improve pain control, opioid use and hospital stay after knee replacement surgery.

Eligible Conditions
  • Postoperative Pain
  • Knee Replacement
  • Total Knee Replacement

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured intraoperatively, in pacu at 4 hours post-op, and at 24,48, and 72 hours post-op.
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured intraoperatively, in pacu at 4 hours post-op, and at 24,48, and 72 hours post-op. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To compare postoperative pain scores and opioid consumption at 48 hours after surgery.
To compare postoperative pain scores and opioid consumption at 72 hours after surgery.
To compare the efficacy of liposomal bupivacaine to conventional bupivacaine for adductor canal blocks in adults scheduled for total knee arthroplasty.
Secondary outcome measures
To compare postoperative opioid consumption measured as morphine milligram equivalents (MME) at 24 hours postoperatively.
To compare total length of postoperative stay following surgical stop time.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Liposomal BupivacaineExperimental Treatment1 Intervention
Adductor canal block using liposomal bupivacaine and conventional bupivacaine
Group II: Standard of CareActive Control1 Intervention
Adductor canal block using conventional bupivacaine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liposomal bupivacaine
2016
Completed Phase 4
~1970

Find a Location

Who is running the clinical trial?

Northern Light Mercy HospitalLead Sponsor
MaineHealthOTHER
72 Previous Clinical Trials
49,447 Total Patients Enrolled
Brian McAllister, MDPrincipal InvestigatorMedical Staff & Chief of Anesthesia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for participants in this experiment?

"According to clinicaltrials.gov, this medical trial is currently open for enrolment with an initial post date of December 1st 2022 and a recent update made on November 22nd 2022."

Answered by AI

How many research participants are currently being monitored in this trial?

"Affirmative. Per the data on clinicaltrials.gov, this research is currently seeking participants for enrollment. It was initially posted to the website on December 1st 2022 and last revised November 22nd 2022; a total of 80 individuals are required from one study site."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Trial of Liposomal Bupivacaine for TKA
2022. "Trial of Liposomal Bupivacaine for TKA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05635916.
~31 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top